0000000000007244

AUTHOR

Cinzia Cajozzo

showing 5 related works from this author

Effects of Infant Formula With Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial

2017

Objectives:The aim of the study was to evaluate the effects of infant formula supplemented with 2 human milk oligosaccharides (HMOs) on infant growth, tolerance, and morbidity. Methods:Healthy infants, 0 to 14 days old, were randomized to an intact-protein, cow's milk-based infant formula (control, n=87) or the same formula with 1.0g/L 2fucosyllactose (2FL) and 0.5g/L lacto-N-neotetraose (LNnT) (test, n=88) from enrollment to 6 months; all infants received standard follow-up formula without HMOs from 6 to 12 months. Primary endpoint was weight gain through 4 months. Secondary endpoints included additional anthropometric measures, gastrointestinal tolerance, behavioral patterns, and morbidit…

0301 basic medicinesafetyMalePediatricsmedicine.medical_specialtyMEDLINEOligosaccharidesWeight Gainlaw.inventionbronchitis03 medical and health scienceschemistry.chemical_compound2'-FucosyllactoseRandomized controlled trialDouble-Blind Method2fucosyllactose; bronchitis; lacto-N-neotetraose; safety; tolerancelawMulticenter trialmedicineAnimalsHumansLacto-N-neotetraoseRespiratory Tract Infectionslacto-N-neotetraose2′fucosyllactose030109 nutrition & dieteticstoleranceMilk Humanbusiness.industryGastroenterologyOriginal Articles: NutritionInfant Newbornfood and beveragesInfantProtective Factorsmedicine.diseaseInfant Formula030104 developmental biologyMilkchemistryInfant formulaPediatrics Perinatology and Child Health2'fucosyllactose bronchitis lacto-N-neotetraose safety toleranceBronchitisFemalemedicine.symptombusinessWeight gainFollow-Up Studies
researchProduct

Growth and safety evaluation of infant formulae containing oligosaccharides derived from bovine milk: a randomized, double-blind, noninferiority trial

2014

A limited number of nondigestible oligosaccharides are available for use in infant formula. This study evaluated growth and safety in infants fed formula supplemented with a mixture of bovine milk-derived oligosaccharides (BMOS). This mixture, which was generated from whey permeate, contains galactooligosaccharides and other oligosaccharides from bovine milk, such as 3′- and 6′-sialyllactose. We hypothesized that growth in infants fed BMOS-supplemented formula would be noninferior to that in infants fed standard formula. Healthy term infants ≤14 days old were randomly assigned to standard formula (control; n = 84); standard formula with BMOS (IF-BMOS; n = 99); or standard formula with BMOS …

Malemedicine.medical_specialtyPediatricsBifidobacterium longumOligosaccharidesGrowthWeight GainGastroenterologyInfant nutritionFecesChild DevelopmentLactobacillus rhamnosusDouble-Blind MethodInternal medicinemedicineAnimalsHumansPediatrics Perinatology and Child HealthGastrointestinal TransitFecesHealthy infantsbiologyAnthropometrybusiness.industryProbioticsInfant NewbornInfantbiology.organism_classificationConfidence intervalInfant FormulaMilkInfant formulaPediatrics Perinatology and Child HealthFood FortifiedVomitingCattleFemalemedicine.symptombusinessFlatulenceWeight gainBovine milk-derived oligosaccharidesResearch ArticleBMC Pediatrics
researchProduct

Epidemiology of Toxoplasma and CMV serology and of GBS colonization in pregnancy and neonatal outcome in a Sicilian population

2013

Background: Aim of our study is to analyze the immunological status in pregnancy for two main TORCH agents, Toxoplasma and Cytomegalovirus (CMV), and the results of group B streptococcus (GBS) screening, assessing the risk for congenital infection in a population from Palermo, Italy. Methods: We retrospectively analyzed the medical records of all inborn live newborns who were born in our division during 2012, gathering information about the mother, the pregnancy and neonatal hospitalization at birth. Whenever data were available, we categorized the serologic status of the mothers for Toxoplasma and CMV. We also considered the results of rectal and vaginal swabs for GBS. We compared the resu…

MaleEpidemiologyAntibodies ProtozoanCytomegalovirusmedicine.disease_causeAntibodies ViralGroup BInfant Newborn DiseasesSerologySettore MED/38 - Pediatria Generale E SpecialisticaPregnancyRisk FactorsPrenatal DiagnosisEpidemiologyPrevalencePregnancy Complications InfectiousIntrauterine infectionSicilyeducation.field_of_studyPregnancy OutcomeCMVMiddle AgedAntibodies BacterialAntibodies Anti-IdiotypicCytomegalovirus InfectionsFemaleToxoplasmaToxoplasmosisAdultmedicine.medical_specialtyAdolescentPopulationCongenital cytomegalovirus infectionGBSRisk AssessmentStreptococcus agalactiaeYoung AdultStreptococcal InfectionsmedicineAnimalsHumanseducationRetrospective StudiesPregnancybusiness.industryResearchInfant Newbornmedicine.diseaseToxoplasmosisStreptococcus agalactiaeImmunoglobulin GImmunologybusinessItalian Journal of Pediatrics
researchProduct

368 Growth of Infant Fed Starter Formula Containing Prebiotics or Symbiotic

2010

Objective: To assess growth of infants fed starter formula supplemented with either prebiotics or symbiotic. In addition, gut microbiota was studied. Methods: Healthy, full term newborns (n= 240) were enrolled before the 14th day of their life and randomly assigned between 3 exclusively formula fed groups: starter IF, starter IF + prebiotics (CMOS+GOS), starter IF + prebiotics (CMOS+GOS) and probiotics (BL999 + LPR). Growth was assessed by body weight gain during 4 months. Gut microbiota profile was examined by measuring fecal counts in Bifidobacteria, Lactobacilli, Enterobacteria, Clostridium at 2 months of age. Incidence of morbidity was appraised. Results: Non inferiority in growth was e…

biologyPrebioticmedicine.medical_treatmentIncidence (epidemiology)Gut florabiology.organism_classificationConfidence intervalAnimal scienceClostridiumStarterPediatrics Perinatology and Child HealthmedicineFecesFull TermPediatric Research
researchProduct

Clinical evaluation of a new starter formula for infants containing live Bifidobacterium longum BL999 and prebiotics.

2006

Abstract Objectives The larger number of bifidobacteria in the intestine of breast-fed infants has been associated with their better health compared with formula-fed infants. We assessed the safety and tolerability of an experimental formula containing 2 × 10 7 colony-forming units of Bifidobacterium longum BL999 and 4 g/L of a prebiotic mixture containing 90% galacto-oligosaccharides and 10% fructo-oligosaccharides. Methods A 7-mo prospective, randomized, reference-controlled, double-blinded trial was performed in infants who were not breast fed after the 14th day of birth. One hundred thirty-eight infants were enrolled and assigned to receive the control or experimental formula until they…

Malemedicine.medical_specialtyBifidobacterium longumEndocrinology Diabetes and Metabolismmedicine.medical_treatmentColony Count MicrobialOligosaccharidesBiologyWeight GainGastroenterologylaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumansFood scienceProspective StudiesProspective cohort studyAdverse effectInfant Nutritional Physiological PhenomenaRespiratory Tract InfectionsNutrition and DieteticsPrebioticProbioticsInfant NewbornInfantbiology.organism_classificationBody HeightInfant FormulaIntestinesInfant formulaTolerabilityConsumer Product SafetyFemaleBifidobacteriummedicine.symptomWeight gainConstipationHeadNutrition (Burbank, Los Angeles County, Calif.)
researchProduct